Abivax (ABVX) Cash from Investing Activities (2024 - 2026)
Abivax (ABVX) posted quarterly Cash from Investing Activities of $579519.1 for Q1 2026, down 49.08% year-over-year from $1.1 million in Q1 2025, and up 103.91% quarter-over-quarter from -$14.8 million in Q4 2025.
Abivax (ABVX) Cash from Investing Activities (2024 - 2026) Analysis & Trends
Abivax's Cash from Investing Activities history runs 3 years deep, the most recent figure standing at $579519.1 for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 49.08% year-over-year to $579519.1; the TTM figure through Mar 2026 stood at -$10.2 million (down 163.3% YoY), while the FY2025 annual figure was -$9.5 million, down 156.53% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $579519.1, up from -$14.8 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $12.4 million in Q2 2024, with the low at -$14.8 million in Q4 2025.
- The 3-year median for Cash from Investing Activities is $1.1 million (2025), against an average of $887626.8.
- Peak annual rise in Cash from Investing Activities reached 99.75% in 2025, while the deepest fall reached 2438.01% in 2025.
- Abivax's Cash from Investing Activities stood at $634745.7 in 2024, then sank by 2438.01% to -$14.8 million in 2025, then jumped by 103.91% to $579519.1 in 2026.
- Business Quant data shows ABVX's Cash from Investing Activities at $579519.1 in Q1 2026, -$14.8 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 579,519.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 579,519.10 |
| Mar 31, 2026 | 579,519.10 |
| Dec 31, 2025 | -14.84 Mn |
| Dec 31, 2025 | -14.84 Mn |
| Sep 30, 2025 | 3.83 Mn |
| Sep 30, 2025 | 3.83 Mn |
| Jun 30, 2025 | 211,676.46 |
| Jun 30, 2025 | 211,676.46 |
| Mar 31, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 634,745.67 |
| Dec 31, 2024 | 634,745.67 |
| Sep 30, 2024 | 1.92 Mn |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 12.45 Mn |
| Jun 30, 2024 | 12.45 Mn |
| Mar 31, 2024 | 2.07 Mn |
| Mar 31, 2024 | 2.07 Mn |